Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation: Metabolic drug interactions
References (33)
- et al.
Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer
Cancer Treat Rev
(1980) - et al.
Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate cytochrome P-450 reduced from rabbit liver microsomes
J Biol Chem
(1974) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding
Anal Biochem
(1976)- et al.
Cytochrome p-450 isozyme LM3b from rabbit liver microsomes
J Biol Chem
(1983) - et al.
Triacetyloleandomycin as inducer of cytochrome P-4503C from rabbit liver microsomes
Biochem Pharmacol
(1985) - et al.
Expression of five forms of microsomal cytochrome P-450 in primary culture of rabbit hepatocytes treated with various classes of inducers
Biochem Pharmacol
(1987) - et al.
Variability in nifedipine pharmacokinetics and dynamics. A new oxidation polymorphism in man
Biochem Pharmacol
(1984) Critical review of pharmacology, pharmacokinetics of vincristine, vindesine, vinblastine
Beitr Onkol
(1981)- et al.
The vinca alkaloids: a new class of oncolytic agents
Cancer Res
(1963) - et al.
Clinical pharmacokinetics of navelbine after oral administration in cancer patients
Cancer Chemother Pharmacol
(1991)
Interpatient and intrapatient variability in vinblastine pharmacokinetics
Clin Pharmacol Ther
Pharmacokinetics of vincristine infusion
Cancer Treat Rep
Pharmacokinetics of vindesine bolus and infusion
Cancer Chemother Pharmacol
Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans
Cancer Res
Clinical pharmacokinetics of vinblastine by continuous intravenous infusion
Cancer Res
Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections
Eur J Cancer Clin Oncol
Cited by (89)
Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies
2021, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesCitation Excerpt :It has been speculated that a critical determinant of this variability is associated with differential expression of polymorphic drug-metabolizing enzymes and/or transporters at sites of elimination. Evidence from in vitro studies has indicated that vincristine undergoes cytochrome P-450 3A (CYP3A)-mediated metabolism [9,10], with CYP3A5 contributing to 75% of the intrinsic clearance of vincristine [11–13]. Interestingly, the incidence of vincristine-induced peripheral neuropathy appears to be lower in patients who functionally express CYP3A5 [14,15], and is increased in patients concurrently treated for fungal infections [16] with azole antifungals that potently inhibit CYP3A-mediated metabolism, such as ketoconazole [17].
Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism
2019, Liver ResearchCitation Excerpt :Chemotherapeutics are one class of drug that is largely implicated in CYP3A interactions.25 For example, the microtubule-destabilizing vinca alkaloids vincristine, vinblastine, and vindesine are substrates of CYP3A4, CYP3A5, and CYP3A7.26,27 Other antimitotics of the same parent class, such as the taxanes paclitaxel and docetaxel, are also metabolized by these enzymes.28,29
Cancer chemotherapy
2013, Drug-Induced Liver DiseaseImproving the Efficacy and Safety of Anticancer Agents - the Role of Pharmacogenetics
2006, Novel Anticancer AgentsGenotyping and phenotyping cytochrome P450: Perspectives for cancer treatment
2006, European Journal of CancerRationally Engineered CYP3A4 Fluorogenic Substrates for Functional Imaging Analysis and Drug-Drug Interaction Studies
2023, Journal of Medicinal Chemistry